PHILADELPHIA--(BUSINESS WIRE)--PolyMedix, Inc. (OTC BB: PYMX), an emerging biotech company developing acute care products for infectious diseases and acute cardiovascular disorders based on biomimetics, announced today that pre-clinical data on the potential uses of the company’s compounds for ophthalmic infections were presented at the 40th Annual Meeting of the Ocular Microbiology and Immunology Group in Las Vegas, Nevada.
